Results 61 to 70 of about 807 (164)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system [PDF]

, 2023
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS).
Jingping Zheng, Jun Lyu, Jun Lyu, Lin Ma, Ling Su, Yankun Liang, Yankun Liang, Yuting Wang   +7 more
core   +1 more source

Clinical Characteristics of SARS-COV-2 Omicron Variant in Acute Myeloid Leukemia and Acute Lymphocytic Leukemia Patients: A Multi-Center Retrospective Study. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background The death rate of hematological malignancies is high, and the death rate of patients with COVID‐19 infection is further increased. Although there have been expert consensus and relevant guidelines to introduce the recommendations of the guidelines for patients with hematological malignancies complicated with COVID‐19 infection ...
Wang L, Mi R, Chen L, Liu J, Yang H, Hu M, Xiaoqiang Z, Zhang Y, Xu X, Liu B, Zhao H, Qianyu L, Liu T, Zhenzhu C, Yao J, Yang Y, Wei X.   +16 more
europepmc   +2 more sources

Evaluation of the efficacy and mechanisms of azvudine in elderly patients with malignant tumors complicated by COVID-19. [PDF]

Acta Pharm Sin B
Sun R, Song Y, Li Z, Wang D, Yu Z.
europepmc   +4 more sources

Antiviral Drugs and Their Roles in the Treatment of Coronavirus Infection [PDF]

, 2022
Viruses are the major pathogenic agents that cause various diseases. Antiviral drugs are used for the treatment of viral infections. Emergent advances of antiviral drugs are focused on two different approaches: targeting the host cell factors or the ...
Alghamdi, Saad, Alsafi, Radi, Asif, Mohammad   +2 more
core   +2 more sources

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, Yin Ying, Jun Zhu, Cheng Fei, Junlei Xiang, Lingli Shen, Qiliang Luo, Yinhuan Wu, Ayiguzhali Wusiman, Chuanwei Xin, Meiling Zhang, Gonghua Li, Xiang Li   +17 more
doaj   +1 more source

Breakthrough of glycobiology in the 21st century [PDF]

, 2023
As modern medicine began to emerge at the turn of the 20th century, glycan-based therapies advanced. DNA- and protein-centered therapies became widely available. The research and development of structurally defined carbohydrates have led to new tools and
Cuihong Tian, Cuihong Tian, Cuihong Tian, Gehendra Mahara, Gehendra Mahara, Jinxiu Zhu, Jinxiu Zhu, Xiaojia Xu, Xiaojia Xu, Xiaojia Xu   +9 more
core   +1 more source

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
wiley   +1 more source

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source

Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study

Journal of Infection and Public Health
Background: Azvudine has become a widely used treatment for COVID-19 in China. Our study aimed to assess the real-world efficacy of azvudine in hospitalized COVID-19 patients during the omicron variant surge.
Rui Han, Youhong Guan, Pulin Li, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang   +6 more
doaj   +1 more source

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyResearch in context

EClinicalMedicine, 2023
Summary: Background: As the COVID-19 pandemic continues to spread, the number of associated deaths continues to increase, especially among those with pre-existing conditions.
Yuming Sun, Liping Jin, Yating Dian, Minxue Shen, Furong Zeng, Xiang Chen, Guangtong Deng   +6 more
doaj   +1 more source